Needham analyst Gil Blum reiterated a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today and set a price target of $62.00. The company's shares closed last Monday at $9.06, close to its 52-week low of $7.57. According to TipRanks.com, Blum is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -40.6% and a 10.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Aeglea Biotherapeutics, and Crispr Therapeutics AG. Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $56.20, representing a 515.6% upside.
https://www.tipranks.com/news/blurbs/rocket-pharmaceuticals-rckt-gets-a-buy-rating-from-needham-2?utm_source=advfn.com&utm_medium=referral
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Jun 2022 to Jul 2022 Click Here for more Rocket Pharmaceuticals Charts.
Rocket Pharmaceuticals (NASDAQ:RCKT)
Historical Stock Chart
From Jul 2021 to Jul 2022 Click Here for more Rocket Pharmaceuticals Charts.